- Home
- MAS vs INCY Comparison
MAS vs INCY Comparison
Compare MAS & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAS
- INCY
- Stock Information
- Founded
- MAS 1929
- INCY 1991
- Country
- MAS United States
- INCY United States
- Employees
- MAS N/A
- INCY N/A
- Industry
- MAS Industrial Specialties
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- MAS Industrials
- INCY Health Care
- Exchange
- MAS Nasdaq
- INCY Nasdaq
- Market Cap
- MAS 14.4B
- INCY 17.0B
- IPO Year
- MAS N/A
- INCY 1993
- Fundamental
- Price
- MAS $69.52
- INCY $89.27
- Analyst Decision
- MAS Buy
- INCY Buy
- Analyst Count
- MAS 14
- INCY 19
- Target Price
- MAS $74.86
- INCY $81.73
- AVG Volume (30 Days)
- MAS 1.7M
- INCY 1.7M
- Earning Date
- MAS 10-29-2025
- INCY 10-28-2025
- Dividend Yield
- MAS 1.78%
- INCY N/A
- EPS Growth
- MAS N/A
- INCY 900.04
- EPS
- MAS 3.76
- INCY 4.37
- Revenue
- MAS $7,663,000,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- MAS N/A
- INCY $16.41
- Revenue Next Year
- MAS $3.22
- INCY $10.86
- P/E Ratio
- MAS $18.49
- INCY $20.16
- Revenue Growth
- MAS N/A
- INCY 18.87
- 52 Week Low
- MAS $56.55
- INCY $53.56
- 52 Week High
- MAS $83.10
- INCY $92.86
- Technical
- Relative Strength Index (RSI)
- MAS 50.37
- INCY 61.79
- Support Level
- MAS $65.41
- INCY $84.38
- Resistance Level
- MAS $70.51
- INCY $92.86
- Average True Range (ATR)
- MAS 1.62
- INCY 2.39
- MACD
- MAS 0.28
- INCY 0.15
- Stochastic Oscillator
- MAS 79.06
- INCY 61.47
About MAS Masco Corporation
Masco manufactures a variety of home improvement and building products. The company's $5-billion plumbing segment, led by the Delta and Hansgrohe brands, sells faucets, showerheads, and other related plumbing fixtures and components. The roughly $3-billion decorative architectural segment primarily sells paints and other coatings under the Behr and Kilz brands, but it also sells builder hardware products.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.